Randomized trial · people
Exenatide: no cognitive benefit in mild cognitive impairment
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this small trial, weekly exenatide did not improve thinking or memory scores in people with mild cognitive impairment, though it did lower fasting blood sugar and body weight.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 32
- Published
- 2024
- Journal
- J Endocrinol Invest
What they tested
The team tested whether slow-release exenatide could help thinking and memory in people with mild cognitive impairment (MCI, early, mild problems with memory and thinking).
How the study was done
A randomized proof-of-concept trial in 32 people with MCI (16 women) ran for 32 weeks. 17 got slow-release exenatide in the trial's 2 mg once-a-week shot under the skin, and 15 got no treatment.

Model. Individual results vary.
What they found
The main measure, the change in the ADAS-Cog11 cognitive test score from start to week 32, did not differ between the groups (p = 0.17). Treatment worked differently by sex (p = 0.04): women given exenatide had worse ADAS-Cog11 scores (p = 0.018), after adjusting for age, schooling, blood sugar problems and starting score. Fasting blood sugar (p = 0.02) and body weight (p = 0.03) went down in the exenatide group.
What it doesn’t show
This was a small, 32-week trial, and the comparison group got no treatment rather than a placebo (a dummy shot). The finding in women comes from a split of an already small group.
The paper
Dei Cas et al. Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial. J Endocrinol Invest. 2024.
The compound
More studies on Exenatide
- Exenatide: lower intracranial pressure in IIH over 12 weeksRandomized trial · people · 2023
- Exenatide did not cut heavy drinking days in alcohol use disorderRandomized trial · people · 2022
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSRandomized trial · people · 2022
- Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placeboRandomized trial · people · 2021
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSRandomized trial · people · 2021
- Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3Randomized trial · people · 2018
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.